Cannabis News

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce, that due to strong investor demand, it has further upsized its previously announced non-brokered private placement of units (the "Units") from $2,700,000 to $3,445,847 (the "Offering") and has completed a second and final tranche closing, raising gross proceeds of $1,118,747 (the "Second Tranche Closing"). The Second Tranche Closing consisted of the issuance of an aggregate of 11,187,475 Units at a price of $0.10 per Unit. Together with the first closing, which was announced on December 24, 2020, the Company has raised total gross proceeds of $3,445,847 pursuant to the Offering, through the issuance of an aggregate of 34,458,475 Units.

Each Unit consists of one common share in the capital of the Company (each a "Share") and one share purchase warrant (each a "Warrant"). Each Warrant entitles the subscriber to acquire one additional Share at a price of $0.25 per Share for a period of two years from the applicable closing date, subject to an accelerated expiry if, on any 10 consecutive trading days occurring after four months and one day has elapsed following the final closing date of the Offering, the closing price of the Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the Canadian Securities Exchange (the "CSE") is greater than $0.35 per Share, in which case Lobe may provide notice to the holders of the Warrants by issuance of a news release that the expiry date of the Warrants will be accelerated to the 30th day after the date on which Lobe issues such news release. No finder's fees were paid in connection with the Offering.

Jonathan Gilbert, Executive Chairman of Lobe, said, "We are extremely pleased with the support we have seen for the Company and the Offering, from both existing and new strategic shareholders, which resulted in upsizing our original offering by over $1.44 million. Our industry is seeing tremendous growth and we intend to build upon this momentum and showcase the Company as a leader by achieving key milestones, including development of our nasal mist device, furthering our pre-clinical studies, closing the Cowlitz sale transaction, and achieving other Company growth initiatives."

Proceeds from the Offering are expected to be used to fund the Company's existing business operations, pre-clinical studies with N-Acetylcysteine and psilocybin, device development/engineering, general working capital, marketing and costs of the Offering. Although the Company intends to use the proceeds of the Offering as described above, the actual allocation of proceeds may vary from the uses set out above depending on future operations, events or opportunities.

The Shares and Warrants comprising the Units issued pursuant to the Offering are subject to a statutory four month and one day hold period from the date of issue in accordance with applicable Canadian securities laws. None of the Units will be registered under the United States Securities Act of 1933, as amended, and none may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Lobe Sciences Ltd.

Lobe is a growth-oriented research, technology & services company that provides financial, management, IP and branding support to businesses. The Company operates a portfolio of companies focused on developing transformational medicines and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, Lobe Sciences creates value through acquisitions and development of assets, products and technologies by leveraging its scientific, engineering, branding and operational expertise supported by strong capital markets acumen.

For further information please contact:

Lobe Sciences Ltd.
Jonathan Gilbert, Executive Chairman
Tel: (949) 505-5623


Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. Certain statements included in this release, including statements regarding the Company's proposed use of proceeds of the Offering, and the key milestones the Company is seeking to achieve, including development of its nasal mist device, furthering pre-clinical studies, completion of the Cowlitz sale transaction and achieving other growth initiatives, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including that the Company may determine to use the proceeds in a manner different than that currently expected; changes to the regulatory environment; and that the current Board and management may not be able to attain the Company's corporate goals, milestones and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.


To view the source version of this press release, please visit

News Provided by Newsfile via QuoteMedia

Lobe Sciences

Lobe Sciences

Keep reading...Show less

Curaleaf Completes Majority Stake Acquisition of Germany's Four 20 Pharma

Deal Solidifies Curaleaf's Strategic Advantage in Germany as the Country Prepares for Adult-Use

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced the completion of its agreement to acquire a 55% stake in Four 20 Pharma GmbH, a fully EU-GMP & GDP licensed German producer and distributor of medical cannabis.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Curaleaf Celebrates Opening of Allentown, Pennsylvania Dispensary

Curaleaf's retail presence grows to 18 locations in Pennsylvania and 137 nationwide

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced the opening of its Allentown dispensary, located at 1801 Airport Rd, Allentown, PA 18109. Curaleaf Allentown is the Company's sixth new location to open within the Keystone State this year, expanding its retail presence to 18 locations in Pennsylvania and 137 nationwide.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
financial chart report

Cannabis Weekly Round-Up: Global Sales to Hit US$57 Billion by 2026

Business research firm BDSA has issued new projections for global cannabis sales in the next few years.

Meanwhile, a new strategic partnership will see one of the biggest cannabis brands make its way over to the European market.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading...Show less
cannabis plant lifted by hand

Metrc CEO: Cannabis Data Helping Regulators Warm Up to Industry

The leader of a cannabis-focused software company sees the industry maturing as data brings clarity to regulators.

Metrc is a provider of cannabis regulatory systems in the US, offering a software-as-a-service program for tracking cannabis along the supply chain. CEO Michael Johnson told the Investing News Network (INN) that access to this type of data has made regulatory officials far more comfortable with the cannabis industry by giving them a clearer picture of the seed-to-sale process.

“The way to de-stigmatize the impressions associated with cannabis is really in providing the insight and the transparency into what's actually happening in the cannabis space,” he said.

Keep reading...Show less
Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto

Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto

Dr. Mac Burnham's team will explore Avicanna's drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures.

Avicanna further expands its current research and commercial focus in Epilepsy which is supported by current medical cannabis sales and on-going research with UHN

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
VIDEO — EY Experts: Canada's Cannabis Market Needs Changes, How Government Can Help

VIDEO — EY Experts: Canada's Cannabis Market Needs Changes, How Government Can Help

EY: Canada's Cannabis Market Needs Changes, How Government Can

A new cannabis market report from business advisory firm EY shows the Canadian industry is in desperate need of changes, including help from the government.

After years of buildup, Canada's cannabis market shows struggling signs at nearly every turn, particularly for publicly traded companies whose past excesses are catching up with them.

The Investing News Network (INN) spoke with two of the leads on the recently released report — Rami El-Cheikh, strategy partner and cannabis lead with EY-Parthenon, and Fred O’Riordan, EY’s Canada national leader of tax policy — to discuss their findings and how the report came to be.

Keep reading...Show less

Latest Press Releases

Related News